BioArctic Receives Extended Funding from VINNOVA

In August 2015, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted extended funding with up to 1.2 million SEK for the development and manufacture of bioceramic powders for use in nerve regeneration. The project aim is to develop a production method for manufacture of bioceramic powders for use in an innovative treatment based on implants for guidance of nerve regeneration in combination with a growth factor, foremost in the treatment of traumatic Spinal Cord Injury.

VINNOVA is The Swedish Governmental Agency for Innovation Systems that supports research and development work of the highest quality. BioArctic is developing a new treatment for traumatic Spinal Cord Injury together with The Department of Clinical Neuroscience and Neurosurgery, Karolinska Institutet and Karolinska University Hospital.

Today, 2.5 million people suffer from spinal cord injuries that essentially lack effective treatment. As a result of pioneering Swedish research, a product has been developed with the potential to provide a successful neurosurgical treatment, which will hopefully improve the function and quality of life of patients suffering from spinal cord injuries.

The forthcoming product is a biodegradable device combined with a growth factor designed to support the growth of nerves in the spinal cord, as well as restoring its function. The product has been developed together with Karolinska Institutet, Elos Medtech, Ångström Laboratories and Protein Sciences (US). The project has been supported by previous grants from The Swedish Governmental Agency for Innovation Systems, Vinnova.

“We are grateful for the support from Vinnova and the development of a production method for manufacturing of bioceramic powders will add an important advantange for this innovative product intended to improve the quality of life for spinal cord injury patients”, says Dr. Gunilla Osswald, CEO of BioArctic Neuroscience AB.